ALS News Today Home | ALS News Today
WEBOct 1, 2024 · Researchers detected changes in the production of several immune signaling proteins, called cytokines, in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — of people with amyotrophic lateral sclerosis (ALS) at diagnosis. These changes also correlated with certain clinical characteristics, and how quickly ...
Amyotrophic Lateral Sclerosis (ALS) Symptoms – ALS News Today
WEBFeb 6, 2023 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which worsening muscle weakness leads to movement problems and other symptoms such as trouble swallowing, speaking, and breathing. Patients also can experience digestive issues, mental health problems, and changes in behavior. Also known as …
News Archives - ALS News Today
WEBModality.AI is teaming up with Target ALS on a clinical study of artificial intelligence (AI) as way to assess changes in speech and motor function in people with amyotrophic lateral sclerosis (ALS). The trial will harness a virtual, conversational AI system, called Tina, intended to detect even…. October 2, 2024 News by Andrea Lobo, PhD.
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
WEBAug 28, 2023 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). It will be AKV9’s first-in-human study and is ...
Types of Amyotrophic Lateral Sclerosis (ALS) – ALS News Today
WEBMar 8, 2023 · Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that can be classified into different types based on factors like genetics, a patient’s family history, and the disorder’s early symptoms. Across all types, ALS is marked by the loss of motor neurons, the nerve cells that control voluntary muscle movements ...
What is Amyotrophic Lateral Sclerosis (ALS)? | ALS News Today
WEBMar 20, 2023 · FAQs. Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder that damages nerve cells and causes disability. The condition also is known as Lou Gehrig’s disease, after the famed New York Yankees baseball player who was diagnosed with the disorder in the late 1930s. ALS specifically damages motor neurons, the nerve cells ...
Relyvrio for ALS – ALS News Today
WEBApr 11, 2024 · Relyvrio (sodium phenylbutyrate and taurursodiol) was an oral treatment approved in the U.S. and Canada to slow disease progression in adults with amyotrophic lateral sclerosis (ALS) that has now been discontinued. The therapy had shown in early clinical trials the ability to slow functional declines and to significantly extend patient survival ...
The stages of amyotrophic lateral sclerosis (ALS) - ALS News Today
WEBJun 13, 2024 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder marked by progressively worsening stages of progression.People with ALS experience muscle weakness and neurological dysfunction, but initial symptoms are typically mild and affect only one part of the body. As the disease becomes more and more severe, these issues gradually spread to the entire body, affecting a range of ...
Amyotrophic Lateral Sclerosis (ALS) Causes | ALS News Today
WEBFeb 2, 2023 · Causes of ALS. The exact cause of amyotrophic lateral sclerosis (ALS) is largely unknown, but a number of factors including genetics, environmental exposures, and lifestyle habits have been linked to an increased risk of ALS. Also known as Lou Gehrig’s disease, named after the famous baseball player who was diagnosed with the …
FDA final approval decision on NurOwn for ALS due by year’s end
WEBJun 8, 2023 · A Phase 3 clinical trial (NCT03280056), completed in 2020, had tested NurOwn in patients with rapidly progressing ALS, who were given three injections of either the therapy or a placebo two months apart.The trial involved 189 adults followed for 28 weeks, or about seven months. The results showed that NurOwn was not significantly more effective than a placebo at slowing disease progression ...